ESR1 and breast carcinoma: Although palbociclib is used primarily in the ER+/HER2− breast cancer treatment, senescence and arrest of cell proliferation have also been explored for metastatic, triple-negative (TNBC, ER−/PR−/HER2−, PR—progesterone receptor) breast cancer treatment.